BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 1,597 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 1,597 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at approximately $6,515,025. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $25.06 on Friday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04. The stock’s 50 day moving average is $26.64 and its 200-day moving average is $25.51.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter last year, the firm posted ($0.21) earnings per share. Equities research analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of BioLife Solutions by 13.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after acquiring an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions in the 4th quarter worth approximately $31,000. Point72 Asset Management L.P. purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at about $11,113,000. ProShare Advisors LLC purchased a new position in shares of BioLife Solutions during the 4th quarter worth $282,000. Finally, Millennium Management LLC raised its stake in BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after acquiring an additional 377,111 shares during the period. 93.24% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BLFS. KeyCorp increased their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Northland Securities lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Finally, HC Wainwright raised their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.